https://03212.iqanda-cme.com/ 2024-12-21T00:26:55+0000 weekly 1 https://03212.iqanda-cme.com/cytokine-immunotherapy-intelligence-zone 2025-01-10T01:48:42+0000 weekly 0.8 https://03212.iqanda-cme.com/resources-and-trials-in-i-o-monotherapeutic-and-combination-therapy 2024-12-28T23:18:56+0000 weekly 0.8 https://03212.iqanda-cme.com/about-cytokine-immunotherapy-intelligence-zone 2024-12-29T17:53:53+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/what-was-it-about-cytokine-based-treatments-targeting-the-il-2-pathway-that-suggested-they-had-potential-to-provide-immune-system-directed-treatment-where-other-therapies-had-failed-and-how-did-the-results-from-artistry-1-inform-your-ana 2024-12-29T18:14:45+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/what-kinds-of-reporters-were-use-to-confirm-and-observe-the-differentiated-biological-and-side-effect-profiles-associated-with-the-current-dosing-strategies-for-nemvaleukin 2024-12-29T18:04:50+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/what-were-the-specific-endpoints-for-artistry-7-and-how-will-the-trial-results-translate-into-possible-approvals-for-nemvaleukin-and/or-icis-for-platinum-resistant-ovarian-cancer-proc 2024-12-28T16:31:18+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/can-you-comment-on-the-enduring-responses-long-term-remissions-observed-with-nemvaleukin-in-artistry-1-and-its-manageable-safety-profile-and-how-it-is-unique-among-novel-engineered-cytokine-fusion-proteins-developed-in-the-immunotherapy- 2024-12-29T18:11:08+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/can-you-summarize-the-key-findings-from-the-artistry-1-trial-with-a-special-emphasis-on-signals-that-part-a-of-the-trial-provided-regarding-the-potential-efficacy-and-safety-of-nemvaleukin-within-the-context-of-a-small-dose-escalation-st 2024-12-29T18:09:05+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/against-this-backdrop-of-positive-signals-for-mucosal-melanoma-observed-in-artistry-1-and-confirmation-that-nemvaleukin-could-be-managed-effectively-and-safely-in-the-outpatient-environment-how-did-you-approach-the-design-of-artistry-6 2024-12-29T18:16:45+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/while-the-formidable-challenges-of-treating-platinum-resistant-ovarian-cancer-are-well-known-can-you-summarize-the-current-approaches-for-treating-these-patient-cohorts-and-specifically-the-trigger-points-and-reported-outcomes-for-immuno 2024-12-28T16:23:33+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/can-you-clarify-a-what-the-novel-engineered-cytokine-fusion-protein-nemvaleukin-is-b-its-differentiating-biological-properties-c-moa-and-d-its-effects-on-immune-centric-cell-subpopulations-such-as-tregs-cd8-and-natural-killer-cells 2024-12-29T18:05:20+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/based-on-the-accumulated-data-thus-far-from-artistry-1-and-interim-monitoring-can-you-characterize-the-side-effect-profile-and-regimen-discontinuation-rates-observed-thus-far-for-nemvaleukin-and-its-manageability-in-the-outpatient-settin 2024-12-28T16:32:20+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/after-taking-note-of-the-signals-for-response-in-mucosal-melanoma-that-were-reported-in-artistry-1-how-did-you-proceed-with-the-design-for-artistry-6-evaluating-the-efficacy-and-safety-of-this-novel-cytokine-fusion-protein-in-mucosal-mel 2024-12-29T18:15:07+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/how-has-novel-engineering-of-nemvaleukin-produced-a-side-effect-profile-that-differs-from-hril-2-and-or-altering-il-2-what-implications-might-this-have-for-an-expanded-role-for-nemvaleukin-in-tumors-other-than-mucosal-melanoma-and-ovaria 2024-12-29T18:06:59+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/what-do-you-hope-to-learn-from-artistry-7-as-it-relates-to-the-efficacy-and-safety-of-nemvaleukin-as-monotherapy-or-as-part-of-combinatorial-therapy-with-immune-checkpoint-inhibitors-and-even-chemotoxic-agents-in-the-setting-of-solid-tum 2024-12-28T19:12:23+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/given-the-artistry-1-trial-how-would-you-envision-the-role-of-nemvaleukin-within-the-larger-context-of-immunotherapy-how-should-cytokines-be-sequenced-in-the-therapeutic-pathway-for-refractory-patients-such-as-those-evaluated-in-artistry 2024-12-29T18:11:42+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/what-were-the-design-rationale-inclusionary-criteria-and-results-of-the-artistry-1-trial-in-which-nemvaleukin-was-evaluated-in-a-phase-1-trial-to-elucidate-dosing-and-signals-suggesting-efficacy-across-a-broad-range-of-solid-tumors 2024-12-28T16:26:08+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/in-addition-to-the-artistry-7-nemvaleukin-trial-what-other-i-o-strategies-are-being-investigated-in-proc 2024-12-29T17:56:26+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/looking-forward-what-types-of-cancer-do-you-think-might-prove-to-be-amenable-to-nemvaleukin-therapy 2024-12-29T18:07:23+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/in-what-specific-ways-is-nemvaleukin-distinct-from-other-cytokines-and-what-ways-does-its-novel-engineering-allow-it-to-take-on-unique-mechanistic-properties-that-differentiates-it-from-all-cytokines-not-just-il-2 2024-12-29T18:05:42+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/what-was-it-about-the-novel-engineered-cytokine-fusion-protein-nemvaleukin-that-led-you-to-revisit-the-il-2-mediated-therapeutic-space-in-search-of-a-treatment-that-would-overcome-previous-limitations-with-high-dose-human-recombinant-il- 2024-12-29T18:15:27+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/on-the-basis-of-what-early-clinical-data-safety-profile-and-mechanistic-features-does-the-fda-typically-approve-a-drug-such-as-nemvaleukin-for-fast-track-designation 2024-12-29T18:17:06+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/can-you-summarize-the-design-of-the-artistry-1-trial-with-nemvaleukin-including-strategies/phases-incorporated-to-evaluate-the-potential-effectiveness-dosing-and-combinatorial-effects-of-nemvaleukin-with-icis-in-the-setting-of-solid-tumo 2024-12-29T18:08:38+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/can-you-kindly-introduce-yourself-to-your-immuno-oncology-colleagues-and-share-with-us-your-scientific-and-clinical-interests-and-experience-focused-on-cytokines-and-their-role-in-immunotherapy-for-cancer 2024-12-29T18:03:44+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/can-you-provide-an-overview-of-the-landscape-of-immunotherapy-for-melanoma-and-its-rarer-subtypes-with-an-emphasis-on-the-role-of-immune-checkpoint-inhibition-its-limitations-and-the-need-for-additional-immuno-oncology-focused-co-therapi 2024-12-29T18:14:01+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/so-that-our-learners-can-better-understand-your-experience-investigational-interests-and-expertise-in-cancer-immunotherapy-and-multi-modal-management-of-ovarian-cancer-can-you-kindly-share-your-current-role-and-affiliations 2024-12-28T16:23:20+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/given-the-refractoriness-of-platinum-resistant-oc-what-does-the-investigational-immunotherapy-landscape-look-like-for-this-patient-subset-with-oc-including-the-use-of-immune-checkpoint-inhibitors-and-cytokine-fusion-proteins-such-as-nemv 2024-12-28T16:23:46+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/based-on-the-results/signals-observed-in-oc-patients-in-artistry-1-how-do-you-design-a-translationally-optimal-trial-with-nemvaleukin-to-assess-its-effectives-as-a-monotherapeutic-vs-combinatorial-agent 2025-08-21T19:27:02+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/looking-forward-when-can-we-expect-early-data-reporting-from-artistry-7-and-what-are-we-likely-to-learn-about-single-agent-vs-combinatorial-approaches-based-on-nemvaleukin-and-why-was-nemvaleukin-fast-tracked-by-the-fda 2024-12-28T16:34:40+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/moving-beyond-investigation-of-nemvaleukin-in-mucosal-melanoma-and/or-other-rare-tumor-types-how-might-the-cancer-immunotherapy-community-think-about-advancing-studies-of-nemvaleukin-across-a-wider-taxonomy-of-tumor-subtypes 2024-12-29T18:17:26+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/although-no-biomarkers-have-yet-been-identified-to-predict-optimal-patient-cohorts-of-nemvaleukin-based-immunotherapy-do-you-envision-a-pathway-to-identifying-biomarkers-in-the-future 2024-12-29T18:12:06+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/can-you-drill-down-into-the-results-for-part-b-of-the-artistry-1-study-and-share-results-in-terms-of-partial-and/or-complete-responses-observed-in-different-tumor-subtypes-including-mucosal-melanoma-advanced-kidney-cancer-and-ovarian-car 2024-12-29T18:09:42+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/based-on-the-strong-signals-for-oc-observed-with-nemvaleukin-in-artistry-1-and-the-yet-to-be-validated-role-of-icis-in-oc-how-did-you-approach-and-concretize-the-design-of-the-artistry-7-trial-focused-on-persons-with-platinum-resistant-o 2024-12-28T16:28:32+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/how-was-il-2-re-engineered-to-generate-a-cytokine-fusion-protein-that-selectively-binds-to-the-intermediate-affinity-il-2-receptor-and-activates-antitumor-cytolytic-effector-natural-killer-cells-and-cd8-t-cells-while-minimizing-expansion 2024-12-28T19:12:03+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/so-that-our-learners-can-better-understand-your-experience-and-expertise-in-cancer-immunotherapy-and-clinical-trial-design-can-you-share-your-current-role-and-affiliations-and-how-you-became-involved-in-the-phase-1-nemvaleukin-trial-arti 2024-12-29T18:08:16+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/why-has-il-2-emerged-as-a-foundational-cytokine-in-cancer-immunotherapy-and-specifically-what-is-its-pivotal-biological-role-in-the-complex-networks-of-cell-cell-and-paracrine-signaling/crosstalk-in-the-tumor-immune-microenvironment 2024-12-29T18:04:08+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/based-on-current-i-o-approaches-to-managing-mucosal-melanoma-why-does-this-refractory-variant-of-melanoma-represent-a-good-model-for-studying-the-efficacy-and-safety-of-a-novel-engineered-cytokine-fusion-protein-such-as-nemvaleukin 2024-12-29T18:14:21+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/what-is-it-about-nemvaleukin-s-novel-engineering-mechanism-of-action-moa-as-well-as-its-manageable-safety-profile-that-makes-it-unique-among-novelly-generated-cytokines-that-have-been-developed-in-the-cancer-immunotherapy-space 2024-12-29T18:15:50+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/what-novel-engineering-features-of-the-cytokine-fusion-protein-nemvaleukin-give-you-reason-to-believe-that-deploying-this-immunotherapy-might-potentiate-the-effectiveness-of-icis-in-the-setting-of-ovarian-cancer-and-other-solid-tumors 2024-12-28T16:23:59+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/although-nemvaleukin-is-being-investigated-in-the-context-of-ici-refractory-disease-what-might-its-potential-role-be-in-chemotherapy-refractory-disease 2024-12-29T18:12:28+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/given-the-current-state-of-knowledge-about-nemvaleukin-at-least-based-on-the-dose-escalation-phase-1-artistry-1-trial-what-is-your-assessment-of-how-this-novel-cytokine-fusion-protein-will-or-can-be-positioned-combined-and/or-sequenced 2024-12-29T18:06:02+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/what-did-we-learn-from-pre-clinical-animal-studies-confirming-that-from-an-immunobiological-mechanistic-perspective-nemvaleukin-stimulated-cd8-and-natural-killer-cells-while-not-concommitantly-activating-the-treg-cell-axis 2024-12-29T18:17:45+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/why-when-the-world-woke-up-to-the-fact-that-cancer-was-also-a-disease-of-the-immune-response-was-there-by-extension-intense-interest-in-a-cytokine-fusion-protein-such-as-nemvaleukin-and-what-was-the-novel-aspect-of-its-engineering 2025-01-07T01:03:39+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/how-effective-has-the-novel-re-engineering-of-the-il-2-cytokine-fusion-protein-nemvaleukin-been-as-far-as-mitigating-side-effects-and-permitting-outpatient-based-administration-and-management-of-this-cytokine-based-treatment-modality 2024-12-29T18:16:26+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/what-specific-actionable-signals-emerged-from-results-of-part-c-of-the-artistry-1-trial-with-respect-to-partial/complete-and/or-enduring-responses-employing-a-combination-of-the-cytokine-fusion-protein-nemvaleukin-in-combination-with-ici 2024-12-29T18:10:10+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/why-and-in-what-ways-can-immune-response-be-restored-in-persons-with-cancer-and-what-role-might-cytokine-based-therapies-such-as-nemvaleukin-help-re-establish-a-favorable-anti-tumor-equilibrium 2024-12-29T18:06:35+0000 weekly 0.8 https://03212.iqanda-cme.com/videos/so-that-your-oncology-colleagues-can-better-understand-your-experience-investigational-interests-and-expertise-in-cancer-immunotherapy-and-treatment-of-musical-melanoma-can-you-kindly-share-your-current-role-and-affiliations 2024-12-29T18:13:40+0000 weekly 0.8 https://03212.iqanda-cme.com/courses/post-test 2025-08-21T16:59:01+0000 weekly 0.8 https://03212.iqanda-cme.com/courses/iqanda-cytokine-immunotherapy-intelligence-zone 2025-08-21T17:42:02+0000 weekly 0.8